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patient-oriented and epidemiological research
An exome-wide sequencing study of lipid response to
high-fat meal and fenofibrate in Caucasians from the
GOLDN cohort
Xin Geng,* Marguerite R. Irvin,† Bertha Hidalgo,† Stella Aslibekyan,† Vinodh Srinivasasainagendra,§
Ping An, ‡ Alexis C. Frazier-Wood,|| Hemant K. Tiwari,§ Tushar Dave,# Kathleen Ryan,#
Jose M. Ordovas,$,**,†† Robert J. Straka,§§ Mary F. Feitosa,‡ Paul N. Hopkins,‡‡ Ingrid Borecki,|| ||
Michael A. Province,‡ Braxton D. Mitchell,# Donna K. Arnett,1,## and Degui Zhi1,*,$$
School of Biomedical Informatics* and School of Public Health,$$ The University of Texas Health
Science Center at Houston, Houston, TX 77030; Departments of Epidemiology† and Biostatistics,§
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Department of Genetics,‡ Washington University School of Medicine, St. Louis, MO 63110; US Department
of Agriculture/Agricultural Research Service Children’s Nutrition Research Center,|| Baylor College of
Medicine, Houston, TX 77030; Department of Medicine, Division of Endocrinology, Diabetes and
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Laboratory,$ Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA
02111; Instituto Madrileño de Estudios Avanzados en Alimentación,** Madrid 28049, Spain; Centro Nacional
Investigaciones Cardiovasculares,†† Madrid 28029, Spain; Department of Experimental and Clinical
Pharmacology Minneapolis,§§ University of Minnesota, MN 55455; Division of Cardiovascular Medicine,‡‡
University of Utah, Salt Lake City, UT 84112; Genetic Analysis Center, Department of Biostatistics,|| ||
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Abstract Our understanding of genetic influences on the
response of lipids to specific interventions is limited. In this
study, we sought to elucidate effects of rare genetic variants
on lipid response to a high-fat meal challenge and fenofibrate (FFB) therapy in the Genetics of Lipid Lowering Drugs
and Diet Network (GOLDN) cohort using an exome-wide
sequencing-based association study. Our results showed that
the rare coding variants in ITGA7, SIPA1L2, and CEP72 are
significantly associated with fasting LDL cholesterol response to FFB (P = 1.24E-07), triglyceride postprandial area
under the increase (AUI) (P = 2.31E-06), and triglyceride
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postprandial AUI response to FFB (P = 1.88E-06), respectively. We sought to replicate the association for SIPA1L2 in
the Heredity and Phenotype Intervention (HAPI) Heart
Study, which included a high-fat meal challenge but not FFB
treatment. The associated rare variants in GOLDN were not
observed in the HAPI Heart study, and thus the gene-based
result was not replicated. For functional validation, we found
that gene transcript level of SIPA1L2 is associated with triglyceride postprandial AUI (P < 0.05) in GOLDN. Our
study suggests unique genetic mechanisms contributing to
the lipid response to the high-fat meal challenge and FFB
therapy.—Geng, X., M. R. Irvin, B. Hidalgo, S. Aslibekyan,
V. Srinivasasainagendra, P. An, A. C. Frazier-Wood, H. K.
Tiwari, T. Dave, K. Ryan, J. M. Ordovas, R. J. Straka, M. F.
Feitosa, P. N. Hopkins, I. Borecki, M. A. Province, B. D.
Mitchell, D. K. Arnett, and D. Zhi. An exome-wide sequencing study of lipid response to high-fat meal and fenofibrate
in Caucasians from the GOLDN cohort. J. Lipid Res. 2018.
59: 722–729.

Abbreviations: AUI, area under the increase; BAM, binary alignment/map; FFB, fenofibrate; GOLDN, Genetics of Lipid Lowering
Drugs and Diet Network; HAPI, Heredity and Phenotype Intervention;
HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; MAF, minor allele
frequency; MB, Madsen and Browning weighted burden test; PPL, postprandial lipemia; QC, quality control; RNA-Seq, RNA sequencing;
SNV, single nucleotide variant; TG, triglyceride; VCF, variant call file.
1
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using DNA methylation and RNA-sequencing (RNA-Seq)
data previously collected in GOLDN.

Dyslipidemia, defined as abnormal levels of lipids
and/or lipoproteins in the blood (1), is a critical modifiable risk factor for chronic diseases, accounting for
almost half of the population attributable risk for adverse cardiovascular events (2). Circulating lipid levels
are influenced by both environment (e.g., diet, smoking, and prescription drugs) and genetic variation; twin
studies estimate the genetic contribution to explain
60% of phenotypic variation (3). Until recently (4),
findings from genome-wide association studies have accounted for about 12% of blood lipid variance. The proportion of unexplained variance (48%) could be
lessened with the inclusion of rare variant analyses, illustrating the important role of the low-frequency polymorphisms in the genetic architecture of lipid traits
(5). These rare variants, which were not covered by
previous genome-wide association studies but contribute to lipid traits, could be located in coding regions, as
well as introns, untranslated regions, and intergene
regions.
To date, such high-resolution genetic investigations of
lipids have focused only on fasting phenotypes, while
knowledge of genetic determinants of lipid response to interventions remains limited. The Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study cohort
provides a unique opportunity to study the effects of rare
genetic variants on response to two interventions, a highfat meal (postprandial lipemia; PPL) and fenofibrate (FFB)
treatment, due to its carefully controlled intervention by
standardizing the environmental perturbation. The highfat meal intervention provides a unique and impactful way
to study dyslipidemia in a dynamic test, not only because
humans spend most of their waking hours in the postprandial state, but also because of the high fat content of Western diets. Furthermore, an elevated postprandial lipid
response, followed by delayed clearance, has been shown
to predict future risk of cardiovascular disease (6). Additionally, the second GOLDN intervention(the 3 week treatment with micronized FFB)creates an opportunity for
pharmacogenomic discovery and a deeper understanding
of individual variation to lipid-lowering drugs (7). Prior
studies in GOLDN have scanned common variants to identify multiple promising determinants of response to both
interventions (8–10); however, they were conducted prior
to the availability of high-resolution genomic data. To augment the discoveries from the Genome-Wide Association
Study (GWAS), account for further missing heritability,
and identify additional functional loci contributing to variation in lipid response to a high-fat meal and treatment
with FFB, we performed an exome-wide sequencing study
in 894 European Americans from the GOLDN study. We
sought to replicate the PPL result using the Heredity and
Phenotype Intervention (HAPI) Heart Study, which included
a high-fat meal challenge but not FFB treatment. In addition, we sought to validate the associations for our findings

METHODS
Study population
GOLDN (clinicaltrials.gov NCT00083369) was designed to
characterize genetic factors that determine response of lipids to
two environmental interventions: a 3 week FFB treatment and a
high-fat meal challenge (8, 9, 11). Only Caucasian families with at
least two siblings were included. Participants were asked to discontinue any lipid-lowering agents (pharmaceuticals or nutraceuticals) for at least 4 weeks prior to the initial visit. GOLDN recruited
and sequenced 894 subjects from 186 families recruited at two
centers (Minneapolis, MN, and Salt Lake City, UT). Of the
894 subjects, 810 participants participated in the high-fat meal
intervention. After that, 797 GOLDN participants received daily
treatment with 160 mg micronized FFB for 3 weeks and were followed for treatment response. Finally, 715 participants participated in another high-fat meal intervention to investigate lipid
response to the high-fat meal while treated with FFB. The population size indicates that we have statistical power ranging from 0.5
2
2
for h locus= 0.02 to 1.00 for h locus= 0.05 or above. Our study has
been approved by the committee for the protection of human
subjects in the University of Texas Health Science Center at Houston and the other institutions, and it abides by the Declaration
of Helsinki principles. Informed consent was obtained from the
human subjects.

Clinical measurements
Clinical lipids including HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), and triglycerides (TGs) were measured in this
study. TG was measured by using the glycerol-blanked enzymatic
method on the Roche COBAS FARA centrifugal analyzer (Roche
Diagnostics Corporation) (10). HDL-C was measured by using the
same procedure as TG after precipitation of non-HDL cholesterol
with magnesium/dextran. LDL-C was measured by using a homogeneous direct method (LDL Direct Liquid Select™ Cholesterol
Reagent; Equal Diagnostics) on a Hitachi 911 Automatic Analyzer. The FFB treatment and the high-fat meal intervention in
GOLDN have been described previously (10, 12). During the
high-fat meal intervention, blood was collected three times for
pre- and post-FFB treatment, respectively: draw 1 (fasting) immediately prior to the meal (0 h), draw 2 approximately 3.5 h after
the meal, and draw 3 approximately 6 h after the meal. We excluded 14 individuals in pre-FFB and 20 individuals in post-FFB
from our postprandial analyses who did not follow the protocol
schedule, which resulted in large drawtime deviations (>1 h).
HDL- and LDL-C were only assessed at draw 1 both before and
after FFB treatment. TG was assessed at each blood draw, which
allowed an analysis of response to the high-fat meal and FFB, and
change in high-fat meal response with FFB.

Library preparation
Genomic DNA from peripheral blood nucleated cells was
extracted by using QIAmp 96 DNA Blood Kits (Qiagen, Hilden,
Germany). The integrity and yield of native genomic DNA was
verified by a PicoGreen assay for quantitation (Invitrogen, Life
Technologies, Carlsbad, CA) and run on a 0.8% agarose gel for
quality control (QC). Illumina paired-end small-fragment libraries
were constructed according to the manufacturer’s recommendations (Illumina Inc., San Diego, CA) with the following exceptions: 1) 500–1,000 ng of native genomic DNA was fragmented by
using the Covaris E220 DNA Sonicator (Covaris, Inc., Woburn,
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MA) to a size range between 100 and 400 bp; 2) Illumina adaptorligated library fragments were amplified in four 50 µl PCR reactions for 18 cycles; and 3) solid-phase reversible immobilization
bead clean-up was used for enzymatic purification throughout the
library process, as well as for final library size selection targeting
300 to 500 bp fragments.

Exome capture and sequencing
Libraries were pooled precapture and hybridized to NimbleGen SeqCap EZ Human VCRome Library kits (Roche NimbleGen, Madison, WI) according to the manufacturer’s protocol.
The concentration of each captured library was determined
through KAPA quantitative PCR (Kapa Biosystems, Inc., Woburn,
MA) according to the manufacturer’s protocol to produce cluster
counts appropriate for the Illumina HiSeq 2000 platform. The
libraries were run on a HiSeq 2000 V3 2×101-bp sequencing run
according to manufacturer recommendations.

Sequence alignment
Illumina sequencing data in FASTQ format were aligned to
the GRCh37-lite reference sequence by using BWA (13) (version
0.5.9) with the parameters: -t 4 -q 5. Duplicates were marked in
each Binary Alignment/Map (BAM) file by using Picard (http://
broadinstitute.github.io/picard/) (version 1.46). If a sample was
sequenced across multiple lanes, the aligned BAM files were
merged by using Picard (version 1.46).

Variant calling, variant call file creation, and annotation
Each BAM file was sorted with potential PCR duplications
removed by using SAMtools (version 1.2.1) (14, 15). Subject-level
single nucleotide variants (SNVs) were called by using the AtlasSNP2 application with a variant call file (VCF) created for each
subject (16). Furthermore, for each chromosome, a populationlevel VCF was created by using the SAMtools mpileup/BCFtools
(13, 14), where the SNVs at all the discovered sites were called and
backfilled in multiple samples by using the original BAMs from all
the GOLDN subjects. Finally, a combined project-level VCF was
created through merging all the 25 population-level VCF files
(chromosomes 1–22, X, Y, and mitochondrial) by using the
GATK-CatVariants (version 3.5) (17–19). Only biallelic mutations
were kept after filtered by using VCFtools (15). For the genotypelevel QC, genotypes with read depth <20 or genotyping quality
<30 were excluded. For the variant-level QC, the mutations were
filtered out if their missing rate was >5%. The project-level VCF
was further annotated by using ANNOVAR (20) according to
hg19 genome assembly/dbSNP (version 138). Four classes of
functional variants (splicing, nonsynonymous, stop-loss, and stopgain) on chromosomes 1–22 were used for association tests (21).

Sample-level QC
Target region breadth by depth for each sample was evaluated
by using RefCov (http://gmt.genome.wustl.edu/packages/refcov/)
v0.3 with a Browser Extensible Data file of target regions provided
by the exome kit manufacturer. We required that >70% of target
bases were covered at >20x; samples below that threshold received
additional (top-up) sequencing.
To confirm sample purity and identity, we compared high-density SNP array genotypes (9) (Illumina OmniExpress) to the SNV
calls obtained from the sequencing data by using SAMtools (15)
version r963, and required >90% genotype concordance to pass a
sample. No samples were excluded due to low concordance.

Phenotype definition
All the lipid values were natural log-transformed to achieve
normality of residuals. Baseline was defined as the value at 0 h

724

Journal of Lipid Research Volume 59, 2018

(i.e., fasting) at the pre-FFB visit. Fasting-level response to FFB was
defined as the difference of log-transformed lipid plasma concentrations at draw 1 between post- and pre-FFB. Three TG pre-FFB
postprandial phenotypes were assessed, including uptake, clearance, and area under the increase (AUI). TG values at each blood
draw were natural log-transformed first. Uptake and clearance
were defined as the slope of the line of TG response from draw 1
to draw 2 and from draw 2 to draw 3, respectively. Next, AUI was
calculated with the transformed value by using the trapezoid rule.
Because draw time deviations from protocol could result in procedural errors in AUI measurement, TG values at 6 h were estimated
by using the values and draw times of draws 2 and 3 by linear
extrapolation. AUI was calculated with the measured values at
draws 1 and 2, and the estimated value at 6 h to mitigate the effect
caused by draw time deviation. The postprandial phenotype response to FFB were the change of PPL phenotype before and after
FFB treatment. These phenotypes included uptake response to
FFB, clearance response to FFB, and AUI response to FFB.

Statistical analysis
Genetic associations were assessed by using linear mixed models using RAREMETALWORKER and RAREMETAL (version
4.13.6) (22, 23). We considered a minimal model and a fully
adjusted model. In the minimal model, all the associations were
adjusted for sex, age, age2, age3, and recruiting center as fixed effects (24, 25). For the FFB analyses, an additional variable measuring the number of pills taken per day (to adjust for compliance)
was included as a covariate. In addition, a kinship coefficient considered as a random effect was used to adjust for family relatedness. In the full model, apart from those covariates included in
minimal models, additional related lipid levels were included as
covariates. For the fasting-level response to FFB and pre-FFB postprandial AUI and uptake, respective baseline levels were included
as covariates. For the pre-FFB postprandial clearance phenotype,
draw 2 lipid level was used as a covariate. For the three postprandial lipid level response to FFB, their corresponding pre-FFB
treatment level and fasting-level response to FFB were included as
covariates (supplemental Table S1).
For gene-based analyses, sequence kernel association test
(SKAT), simple burden test, Madsen and Browning weighted burden test (MB), and variable threshold test were utilized with multiple frequency thresholds for variant inclusion (MAF < 5% and
1%) (26–28).
Bonferroni corrections were used for both single-variant and
gene-based associations. The significant signals were filtered out if
they were driven by variants carried by less than three individuals
or one single family.

Replication
We sought to replicate our associations for TG postprandial
phenotypes using the HAPI Heart Study (29), in which postprandial TG levels were measured at 0, 1, 2, 3, 4, and 6 h after 770 Old
Order Amish participants underwent a high-fat feeding intervention identical to the one used in GOLDN. More study procedure
details can be found in previous reports (10, 29). HAPI Heart
Study participants were genotyped as part of the Trans-Omics for
Precision Medicine effort using whole-genome sequencing methods. TG postprandial phenotypes were defined in the HAPI Heart
Study similarly as described above in GOLDN but calculated with
measured values at 0, 3, and 6 h. Demographic and clinical characteristics of the HAPI Heart Study are listed in supplemental
Table S2.
The association of GOLDN top hits in the replication cohort
was tested by using RAREMETALWORKER with an identical
model to GOLDN. Next, we also performed a joint meta-analysis of
GOLDN top hits across all participating cohorts using RAREMETAL.
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Functional validation
We sought to validate the associations for our findings using
DNA methylation and RNA-Seq data previously collected in
GOLDN. CpG site methylation was quantified by using the Illumina (San Diego, CA) Infinium Human Methylation450 Beadchip with 991 participants as described previously (24). The CpG
sites within the genes containing significantly associated variants
and the intergenic CpG sites near these genes were examined to
test whether their methylation levels were associated with lipid levels
or not by using linear mixed models.
For transcriptional profiling, 100 unrelated GOLDN participants were selected from the extremes of the BMI distribution.
RNA was extracted from buffy coats by using the TRIzol method
(ThermoFisher Scientific, Waltham, MA), and the quality was
evaluated by using Bioanalyzer (Agilent Technologies, Santa
Clara, CA). After sequencing and alignment, we fitted linear
mixed models to test for associations between gene transcript
level and lipid phenotypes.

Results
Demographic and clinical characteristics
Demographic and clinical characteristics of the study
subjects are listed in Table 1 and supplemental Table S2.
From 186 families, we included 435 males and 459 females
from the GOLDN study. Levels of TG, LDL-C, and HDL-C
after FFB treatment were significantly different from pretreatment levels (P  0.05) (Table 1). As described before
(25), TG levels increased significantly during the first 3.5 h
and decreased significantly from 3.5 to 6 h after both highfat meals (pre- and post-FFB) (P  0.05). Moreover, the
post-FFB clearance was significantly different than the pre-FFB
clearance (P  0.05).
Exome sequencing
On average, 61,235,513 (SD = 11,606,103) reads per
sample were generated, and 98.9% reads were mapped to
the reference genome. In total, 968,507 variants (124,661
exonic variants) were called. The average read depth for
each sample across the 968,507 variants ranged from 25.5
to 111.2 (mean = 52.3). After filtering out variants with
missing rate > 0.05, genotype quality < 30, and read depth
< 20, a total of 83,577 functional variants were kept, located

within exonic regions of 16,333 genes on autosomes. Of
those, 74,216 rare variants with minor allele frequency
(MAF) < 0.05 were located in 14,795 genes, while 66,605
rare variants with MAF < 0.01 were located in 14,521 genes.
Transitions/transversions ratio of SNPs that passed QC was
2.61, and the heterozygous/homozygous ratio was 1.74. A
small percentage (2.8%) of these 83,577 variants were included in our previous GWAS (8), for which the genotype
concordance was 98.8%. Across the autosomes, each participant had an average of 1 splicing, 4 stop-loss, 23 stopgain, and 3,154 nonsynonymous biallelic variants. Rare
variants (MAF < 0.05) were more enriched in variants of
greater functional impact (Fig. 1), which may indicate purifying selection of deleterious alleles (30, 31).
Association tests
By using the Bonferroni correction for multiple testing,
P < 5.98E-07 (0.05/83,577) was selected as the exome-wide
significance threshold for the single-variant association
test, and no single variant was significant by using minimal
or full models.
For the gene-based burden test, the Bonferroni corrected significance thresholds were defined as P < 3.38E-06
(0.05/14,795) and 3.44E-06 (0.05/14,521) with MAF
thresholds of 0.05 and 0.01, respectively. By using full models,
the rare coding variants in three genes, ITGA7, SIPA1L2,
and CEP72, were significantly associated with LDL-C fasting
level response to FFB, pre-FFB postprandial TG AUI, and
postprandial TG AUI response to FFB, respectively (Table 2,
Fig. 2). In consideration of the minimally adjusted model,
only the rare coding variants in ITGA7 and CEP72 were still
significantly associated with the same traits, while the rare
coding variants in SIPA1L2 (P = 5.58E-06) did not reach
the statistical significance threshold. Below, we present results based on the MAF threshold of 0.01 for the full model
unless otherwise noted. The severities of rare variant effects, predicted by PolyPhen2 (32) or SIFT (33), are listed
in Table 2.
Associations with rare variants from known lipid genes
from previous GOLDN studies
We also sought to replicate known candidate genes, including APOA5 (34), APOE (11), and APOC3 (35), which
were reported to carry variants significantly associated with

TABLE 1. Clinical characteristics of samples in GOLDN
Pre-FFB
Phenotype
2

BMI, kg/m
Glucose, mg/dl
Systolic blood pressure, mmHg
Diastolic blood pressure, mmHg
HDL, 0 h, log(mg/dl)
LDL, 0 h, log(mg/dl)
TG, 0 h, log(mg/dl)
TG, 3.5 h, log(mg/dl)
TG, 6 h, log(mg/dl)
TG uptake, log(mg/(dl*h))
TG clearance, log(mg/(dl*h))
TG AUI, mg*h/dl

Post-FFB

Mean

SD

Mean

SD

28.5
101.51
116.08
68.57
3.81
4.78
4.75
5.38
5.23
0.17
0.06
6.71E-04

5.6
18.74
16.82
9.6
0.27
0.27
0.59
0.57
0.70
0.08
0.13
3.37E-04

—
99.44
—
—
3.86
4.60
4.36
4.99
4.80
0.17
0.08
6.65E-04

—
19.05
—
—
0.26
0.31
0.52
0.55
0.61
0.09
0.13
3.16E-04

The values were log-transformed.
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7
MB
Burden
CEP72
Postprandial TG AUI response to FFB

1.88E-06
2.01E-06

22
MB
2.31E-06
SIPA1L2
Postprandial TG AUI

Rare variant #: the number of rare variant loci within the candidate genes; rare allele carrier #: the number of samples who carry the rare variant; variant P: P value for the null hypothesis of the
association test between the rare variant and its corresponding trait. The variants were carried by different families if rare allele carrier number is greater than 1.

1.7E-05
0.01
NA
4.8E-03
NA
1.5E-05
8.4E-04
4.5E-04
2.3E-04
2.3E-04
1.5E-03
NA
F->L probably damaging
T->I possibly damaging
M->T damaging
D->N possibly damaging
A->T tolerated
G->A tolerated
T->A benign
P->L probably damaging
K->R possibly damaging
D->N benign
R->W possibly damaging
T->I benign
1
15
4
4
4
3
1
1
1
1
11
1
—
+
+
+
+
+
+
—
—
—
—
—
5.13E-02
1.74E-07
7.00E-02
9.76E-02
6.83E-02
4.24E-02
4.21E-03
5.85E-05
5.85E-05
5.85E-05
3.40E-02
1.97E-02
12:56101365:G:T
12:56105894:G:A
1:232564197:A:G
1:232581366:C:T
1:232626760:C:T
1:232650307:C:G
1:232650941:T:C
5:635508:C:T
5:637668:A:G
5:637673:G:A
5:640669:C:T
5:644511:C:T
12
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Replication results
The significant gene SIPA1L2 for TG postprandial AUI
was tested for association in the HAPI Heart Study. In total,
seven exonic functional SNPs were identified in this gene
within the HAPI Heart Study, one of which was shared with
GOLDN (supplemental Tables S5 and S6). None of the
seven SNPs in HAPI Heart Study was significant (supplemental Table S5). The association of SIPA1L2 with TG
postprandial AUI in the HAPI Heart Study was not significant (P = 0.97) according to a gene-based test, and the
effect direction was different from that in GOLDN. The

Trait

one or more lipid class in GOLDN (for response phenotypes), as well as fasting lipids in other studies (21). The
variants identified in those genes and their P values are
listed in supplemental Tables S3 and S4. Overall, we report
that APOA5 and APOE, but not APOC3, showed associations with one or more GOLDN lipid traits in single-variant
or gene-based tests. We note that some known mutations in
these three genes were not identified in our study or were
filtered out during QC. For example, a known missense
SNP (rs7412) in APOE was filtered out because of low reading depth.

Significant
gene P-value

Fig. 1. Fraction of SNPs with different MAF range within different
categories. The categories include synonymous, nonsynonymous,
and loss of function (i.e., splicing, stopgain, and stoploss). The y
axis indicates the fraction of SNPs with a different MAF range.

TABLE 2. Significant genes and their variants for plasma lipid level according to gene-based test using full model

Mutation effect

Allele frequency
in ExAC
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Fig. 2. Distribution of residuals for regression of
phenotypes on their covariates. The diamonds indicate corresponding residual values of rare variant carriers. The x axis is the Z score for residuals. The y axis
is the sample counts.

FFB treatment protocol was not a part of the HAPI Heart
study, and thus we could not attempt replication for ITGA7
or CEP72.
Functional validation results
We examined whether differential methylation at cytosine–guanine dinucleotides (CpGs) within and neighboring our top gene findings were associated with our lipid
traits. After Bonferroni correction for multiple testing, no
methylation of CpG sites within or neighboring those three
genes was associated with lipid intervention traits.
We also examined the gene transcript level of candidate
genes using RNA-Seq data of GOLDN. The gene transcript
level of SIPA1L2 was significantly associated with TG postprandial AUI (P  0.05), and the gene transcript level of
ITGA7 was borderline associated with LDL-C fasting level
response to FFB (P = 0.07).

Discussion
High-resolution genetic investigations of lipids have focused only on fasting phenotypes. In this study, we sought
to elucidate effects of rare genetic variants on lipid response to a high-fat meal and FFB treatment using an
exome-wide sequencing-based association study for the first
time. Here, we present preliminary evidence of genetic determinants of lipid response to two interventions. Those
genes include ITGA7, SIPA1L2, and CEP72. The SIPA1L2
gene transcript level was associated with the TG postprandial response. In addition, we identified associations related with lipid response to two interventions in candidate
genes whose common variants were found to be associated
with baseline lipid phenotypes in previous studies.
We identified three genes with rare coding-sequence
mutations whose carriers exhibited clinically relevant
phenotypic differences compared with noncarriers. Previous studies offer insights into the observed associations.
For example, common polymorphisms in ITGA2 (an ITGA7
homolog) were associated with coronary atherosclerosis
in a candidate gene association study of the Chinese Han

population (36). Variants in CEP164 and CEP68, which are
homologs of CEP72, were reported to be associated with
TG and LDL-C fasting levels (5, 21, 37). Although no study
has indicated that SIPA1L2 is related to lipid level so far,
the gene transcript level of SIPA1L2 was significantly associated with TG postprandial AUI (P  0.05) in the GOLDN
RNA-Seq study. Overall, rare variants in these genes warrant further study in relation to PPL and FFB treatment
aimed at curbing elevated fasting and postprandial lipid
levels.
Previous GOLDN candidate gene studies have interrogated variants in APOA5, APOE, and APOC3 (11, 34, 35)
with respect to lipid traits. Although the functions of these
genes in controlling lipid fasting levels are well known, we
lack the knowledge of the effects of their mutations on
lipid level response to interventions. Lai et al. (34) studied associations between an APOA5 variant (rs3135506,
chr11:116662407) and baseline TG and TG response to
FFB, as well as postprandial TG. Our study replicated their
findings (supplemental Table S3), where APOA5 rare variant carriers exhibited significantly higher baseline TG and
lower baseline HDL-C levels (P  0.05) compared with
noncarriers. After 3 weeks of FFB treatment, reduction of
TG fasting level in APOA5 rare variant carriers was significantly larger than that in noncarriers (P  0.05), and the
HDL-C response was also higher (34). Our study adds to
that study by identifying that rs3135506 in APOA5 was also
associated with TG postprandial clearance slope, a trait not
previously analyzed. The effects of two APOE variants
(rs7412 and rs429358) on TG levels has also been examined in GOLDN (11). Our study further showed rs429358
in APOE to be associated with baseline LDL-C and LDL-C
response to FFB. Liu et al. (35) reported that two intronic
variants in APOC3 were associated with enhanced TG
response to FFB treatment. Our study did not cover
those variants, and we did not uncover any exonic APOC3
variations with allele count greater than two (supplemental
Tables S3 and S4). rs76353203, a stop-gain variant in APOC3,
was reported to be associated with decreased baseline TG,
increased baseline HDL-C, and decreased baseline LDL-C
in the Amish population (38). In our study, we observed
Study of lipid response to interventions in GOLDN
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consistent directions of this association, but the variant was
carried by only one sample, and the association was not
significant. Overall, these results continue to add to the body
of literature on these important lipid candidate genes.
This study has several limitations. The efficiency of capture probes varies considerably for exome sequencing
(supplemental Fig. S1). Thus, the read depths for partial
SNPs were low, so that they were excluded by the QC procedure. For example, rs7412, which was known to be associated with lipid levels, was excluded due to low read depth.
In addition, participants from the HAPI Heart Study were
recruited from the Amish community of Lancaster County,
PA, who are descendants of about 200 original founding
individuals (facilitating population drift and potential
enrichment for rare variants) (29), while the GOLDN
cohort was recruited from families of general European
ancestry. Thus, external replication of rare variants was
likely hindered by the private nature of such polymorphisms to individual populations. Also, cohorts with pharmaceutical intervention phenotypes for lipid traits and
exome sequencing are rare, so proper replication of the
pharmacogenetic effects is difficult. Moreover, genetic
variants in introns, UTR regions, and intergene regions
were not examined in our study, which could contribute to
the unexplained variance.

Conclusion
In our study, novel rare variants in three genes, ITGA7,
SIPA1L2, and CEP72, associated with lipid response to a
high-fat meal and/or a 3-week FFB treatment were found.
Moreover, the gene transcript level of SIPA1L2 was associated with the postprandial TG AUI. We identified new intervention trait associations within two known candidate
genes (APOA5 and APOE). In conclusion, we found novel
genetic variants that contribute to lipid intervention traits
and revealed potential underlying molecular mechanisms,
which may inform biomarkers of disease risk and treatment
targets.
We gratefully acknowledge the studies and participants who
provided biological samples and data for TOPMed.
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